NCT05537571Phase 2Completed

Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events

Study sponsor: Silence Therapeutics plc · SLN

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-01-11Actual
Enrollment · participants180Actual
Source updated2025-07-01Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview